WO2023016828A3 - Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation - Google Patents

Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation Download PDF

Info

Publication number
WO2023016828A3
WO2023016828A3 PCT/EP2022/071381 EP2022071381W WO2023016828A3 WO 2023016828 A3 WO2023016828 A3 WO 2023016828A3 EP 2022071381 W EP2022071381 W EP 2022071381W WO 2023016828 A3 WO2023016828 A3 WO 2023016828A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding
specifically
m6pr
protein
isvd
Prior art date
Application number
PCT/EP2022/071381
Other languages
French (fr)
Other versions
WO2023016828A2 (en
Inventor
Nico Callewaert
Justine NAESSENS
Linde VAN LANDUYT
Original Assignee
Vib Vzw
Universiteit Gent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vib Vzw, Universiteit Gent filed Critical Vib Vzw
Priority to CA3228014A priority Critical patent/CA3228014A1/en
Publication of WO2023016828A2 publication Critical patent/WO2023016828A2/en
Publication of WO2023016828A3 publication Critical patent/WO2023016828A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

The present invention relates to protein binding agents specifically binding the human cation-independent mannose-6-phosphate receptor (CI-M6PR), more specifically polypeptide agents comprising an immunoglobulin single variable domain (ISVD) specifically binding CI-M6PR at nano- to picomolar affinity, fused to further protein binding agents specifically binding extracellularly-accessible protein targets, such as membrane proteins, extracellular or secreted proteins. More specifically said CI-M6PR-specific ISVD recognizes CI-M6PR N-terminal domains 1, 2 and / or 3, thereby providing for means and methods for internalization, lysosomal targeting and degradation of agents comprising said ISVD, and of targets bound to said protein binding agents. The CI-M6PR binders disclosed herein are thus linked or fused to a further protein binding agent, in particular another antigen-binding protein, such as an ISVD or antibody, relevant for use in therapy, more specifically for treatment of diseases affected by said target antigen bound by said antigen-binding protein. More specifically disclosed herein are CI-M6PR ISVD fusions to antigen-binding proteins specifically binding EGFR, for treatment of cancer.
PCT/EP2022/071381 2021-07-30 2022-07-29 Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation WO2023016828A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3228014A CA3228014A1 (en) 2021-07-30 2022-07-29 Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21188724.5 2021-07-30
EP21188724 2021-07-30

Publications (2)

Publication Number Publication Date
WO2023016828A2 WO2023016828A2 (en) 2023-02-16
WO2023016828A3 true WO2023016828A3 (en) 2023-03-30

Family

ID=77155641

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2022/071381 WO2023016828A2 (en) 2021-07-30 2022-07-29 Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation

Country Status (2)

Country Link
CA (1) CA3228014A1 (en)
WO (1) WO2023016828A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100467A2 (en) * 2015-12-08 2017-06-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
US20180355017A1 (en) * 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
WO2020132100A1 (en) * 2018-12-19 2020-06-25 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules for lysosomal targeting and related compositions and methods
WO2020185069A1 (en) * 2019-03-08 2020-09-17 Linxis B.V. Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
ES2162823T5 (en) 1992-08-21 2010-08-09 Vrije Universiteit Brussel IMMUNOGLOBULINS DESPROVISTAS OF LIGHT CHAINS.
AU6796094A (en) 1993-04-29 1994-11-21 Raymond Hamers Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
FR2708622B1 (en) 1993-08-02 1997-04-18 Raymond Hamers Recombinant vector containing a sequence of a structural lipoprotein gene for the expression of nucleotide sequences.
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
EP1051493A2 (en) 1998-01-26 2000-11-15 Unilever Plc Method for producing antibody fragments
BR9916765A (en) 1999-01-05 2001-09-25 Unilever Nv Process for producing an immunoadsorbent material, use of a protein that is linked via a covalent bond to an antibody fragment, immunosorbent material, use of a material, and, diagnostic test kit
ATE276359T1 (en) 1999-01-19 2004-10-15 Unilever Nv METHOD FOR PRODUCING ANTIBODY FRAGMENTS
WO2000065057A1 (en) 1999-04-22 2000-11-02 Unilever Plc Inhibition of viral infection using monovalent antigen-binding proteins
US6479280B1 (en) 1999-09-24 2002-11-12 Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw Recombinant phages capable of entering host cells via specific interaction with an artificial receptor
AU2161501A (en) 1999-11-29 2001-06-25 Unilever Plc Immobilized single domain antigen-binding molecules
AU1859201A (en) 1999-11-29 2001-06-12 Unilever Plc Immobilisation of proteins
EP1134231B1 (en) 2000-03-14 2009-04-15 Unilever N.V. Antibody heavy chain variable domains against human dietary lipases, and their uses
AU2001268855A1 (en) 2000-05-26 2001-12-03 National Research Council Of Canada Single-domain antigen-binding antibody fragments derived from llama antibodies
DK1360207T3 (en) 2000-12-13 2011-09-05 Bac Ip B V Protein array of variable domains of heavy immunoglobulin chains from camels
WO2003025020A1 (en) 2001-09-13 2003-03-27 Institute For Antibodies Co., Ltd. Method of constructing camel antibody library
JP2005289809A (en) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) Mutant heavy-chain antibody
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
US20050037358A1 (en) 2001-12-21 2005-02-17 Serge Muyldermans Method for cloning of variable domain sequences
EP1461085A2 (en) 2002-01-03 2004-09-29 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Immunoconjugates useful for treatment of tumours
AU2003286003B2 (en) 2002-11-08 2011-05-26 Ablynx N.V. Stabilized single domain antibodies
WO2005044858A1 (en) 2003-11-07 2005-05-19 Ablynx N.V. Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
JP2006524036A (en) 2002-11-08 2006-10-26 アブリンクス エン．ヴェー． Single domain antibodies targeting tumor necrosis factor alpha and uses thereof
EP2390270A1 (en) 2003-01-10 2011-11-30 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
NZ563392A (en) 2005-05-20 2009-12-24 Ablynx Nv Improved Nanobodies(TM) for the treatment of aggregation-mediated disorders
JP2009511032A (en) 2005-10-11 2009-03-19 アブリンクス エン．ヴェー． Nanobodies and polypeptides for EGFR and IGF-IR
US8629244B2 (en) 2006-08-18 2014-01-14 Ablynx N.V. Interleukin-6 receptor binding polypeptides
CN101663319A (en) 2007-02-21 2010-03-03 埃博灵克斯股份有限公司 Be used for the treatment of at the aminoacid sequence of vascular endothelial growth factor and the polypeptide that comprises it and be characterised in that excessive and/or pathologic vessels takes place or the illness and the disease of neovascularization
CN104231082B (en) 2007-05-24 2018-12-21 埃博灵克斯股份有限公司 The amino acid sequence for RANK-L for treating bone disease and illness and the polypeptide including it
SG10201805064SA (en) 2011-06-23 2018-07-30 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
PT3248986T (en) 2014-05-16 2022-04-05 Ablynx Nv Immunoglobulin variable domains
CN115803345A (en) 2020-03-05 2023-03-14 Umc乌得勒支控股有限公司 Membrane ubiquitin ligase targeting protein degradation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017100467A2 (en) * 2015-12-08 2017-06-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
US20180355017A1 (en) * 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
WO2020132100A1 (en) * 2018-12-19 2020-06-25 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules for lysosomal targeting and related compositions and methods
WO2020185069A1 (en) * 2019-03-08 2020-09-17 Linxis B.V. Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation

Also Published As

Publication number Publication date
CA3228014A1 (en) 2023-02-16
WO2023016828A2 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
JP7360377B2 (en) Binding protein drug conjugates including anthracycline derivatives
Schmidt et al. Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors
EP2777714A1 (en) Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
JP2019502363A (en) Anti-ROR1 antibody
EA201990781A9 (en) ANTI-STEAP2 ANTIBODIES, CONJUGATES ANTIBODY MEDICINES AND BISSPECIFIC ANTIGEN BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND THEIR APPLICATION
Niesen et al. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities
CA2488896A1 (en) Multifunctional polypeptides
US20100015661A1 (en) Antibody-rnase-conjugate
Lázaro-Gorines et al. A novel carcinoembryonic antigen (CEA)-targeted trimeric immunotoxin shows significantly enhanced antitumor activity in human colorectal cancer xenografts
Niesen et al. A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor
Yuan et al. Challenges associated with the targeted delivery of gelonin to claudin-expressing cancer cells with the use of activatable cell penetrating peptides to enhance potency
Gilabert-Oriol et al. Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells
Proshkina et al. Bifunctional toxin DARP-LoPE based on the HER2-specific innovative module of a non-immunoglobulin scaffold as a promising agent for theranostics
Feng et al. Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes
Sokolova et al. Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency
CN106589131B (en) Fusion protein 4D5Fv-PE25, and preparation method and application thereof
MX2021011330A (en) Claudin-6 antibodies and drug conjugates.
Akbari et al. Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A
WO2023016828A3 (en) Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
Park et al. Selective and Effective Cancer Treatments using Target‐Switchable Intracellular Bacterial Toxin Delivery Systems
Altenschmidt et al. Targeted therapy of Schwannoma cells in immunocompetent rats with an erbB2‐specific antibody‐toxin
Rong et al. Site-specific dinitrophenylation of single-chain antibody fragments for redirecting a universal CAR-T cell against cancer antigens
Hidalgo et al. Switchable CAR T cell strategy against osteosarcoma
Falahatgar et al. Expression and evaluation of huscfv antibody-pe40 immunotoxin for target therapy of egfr-overexpressing cancers
RU2576232C1 (en) Recombinant immunotoxin, specific to the cells expressing her2 receptor

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22808592

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 3228014

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2022808592

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022808592

Country of ref document: EP

Effective date: 20240229